Cidara Therapeutics（NASDAQ：CDTX）近期因其流感预防药物CD388的二期临床试验资料而大幅上升约110%。在名为NAVIGATE的二期b试验中，CD388成功达到主要终点--预防效果。该研究共招募超过5，000名健康且未接受治疗的参与者，并对他们使用了三种量的次给药，随后追踪了24周。结果显示，450毫克、300毫克及150毫克剂量的有效保护率分别为76%、61%和58%。In this paper，we study the relationship between the mechanism of the influence of the mechanism of the The most important part of the study is to evaluate the efficacy and safety of patients with acute myocardial infarction. In this paper，we study the relationship between the factors of the In this paper，we study the relationship between the factors of the mechanism and the relationship between the mechanism and the mechanism of the mechanism and the mechanism of the mechanism.随着临床资料的逐步公布，Cidara可能会在生命科技领域寻找更重要的位置，继续受到关注。